Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.
Pelvic exenteration
curative
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
12
08
2019
revised:
01
09
2019
accepted:
03
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
14
3
2020
Statut:
ppublish
Résumé
Although pelvic exenteration is an aggressive surgical procedure, it remains almost the only curative solution for patients diagnosed with large pelvic malignancies. We present a series of 100 patients submitted to pelvic exenteration with curative intent. The origin of the primary tumor was most commonly represented by cervical cancer, followed by, endometrial cancer, rectal cancer, ovarian cancer and vulvo-vaginal cancer. An R0 resection was confirmed in 68 cases, while the remaining 32 cases presented lateral positive resection margins or perineal positive margins. The postoperative morbidity rate was 37% while the mortality rate was 3%. As for the-long term outcomes, the median overall survival time was 38.7 months, being most significantly influenced by the origin of the primary tumor. Although pelvic exenteration is still associated with an increased morbidity, an important improvement in the long-term survival can be achieved, especially if radical resection is feasible.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Although pelvic exenteration is an aggressive surgical procedure, it remains almost the only curative solution for patients diagnosed with large pelvic malignancies.
PATIENTS AND METHODS
METHODS
We present a series of 100 patients submitted to pelvic exenteration with curative intent.
RESULTS
RESULTS
The origin of the primary tumor was most commonly represented by cervical cancer, followed by, endometrial cancer, rectal cancer, ovarian cancer and vulvo-vaginal cancer. An R0 resection was confirmed in 68 cases, while the remaining 32 cases presented lateral positive resection margins or perineal positive margins. The postoperative morbidity rate was 37% while the mortality rate was 3%. As for the-long term outcomes, the median overall survival time was 38.7 months, being most significantly influenced by the origin of the primary tumor.
CONCLUSION
CONCLUSIONS
Although pelvic exenteration is still associated with an increased morbidity, an important improvement in the long-term survival can be achieved, especially if radical resection is feasible.
Identifiants
pubmed: 31662557
pii: 33/6/2205
doi: 10.21873/invivo.11723
pmc: PMC6899142
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
2205-2210Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Gynecol Oncol. 2006 May;101(2):261-8
pubmed: 16426668
Arch Gynecol Obstet. 2019 Jul;300(1):161-168
pubmed: 31011878
Hepatogastroenterology. 2003 May-Jun;50(51):700-3
pubmed: 12828064
Dis Colon Rectum. 2000 Mar;43(3):312-9
pubmed: 10733111
Cancer. 1948 Jul;1(2):177-83
pubmed: 18875031
Gynecol Oncol. 2010 Jan;116(1):38-43
pubmed: 19878978
Lancet Oncol. 2006 Oct;7(10):837-47
pubmed: 17012046
Anticancer Res. 2015 Oct;35(10):5539-42
pubmed: 26408722
Curr Oncol Rep. 2015 Mar;17(3):435
pubmed: 25687807
Anticancer Res. 2015 Oct;35(10):5543-6
pubmed: 26408723
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):427-35
pubmed: 9457832
World J Surg Oncol. 2012 Jun 15;10:110
pubmed: 22703863
World J Surg. 2010 Sep;34(9):2177-84
pubmed: 20512493
Br J Surg. 2009 Feb;96(2):191-6
pubmed: 19160364
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
In Vivo. 2017 Jul-Aug;31(4):719-722
pubmed: 28652446
Lancet Oncol. 2003 Mar;4(3):158-66
pubmed: 12623361
Ann Surg Oncol. 2006 May;13(5):612-23
pubmed: 16538402
Oncology. 2000;58(1):31-7
pubmed: 10644938
Eur J Surg Oncol. 2006 Oct;32(8):859-65
pubmed: 16690243